Livzon Pharmaceutical Group Inc. (HKG:1513)

Market Cap	39.21B
Revenue (ttm)	12.60B
Net Income (ttm)	2.24B
Shares Out	n/a
EPS (ttm)	2.46
PE Ratio	17.50
Forward PE	16.57
Dividend	1.20 (3.07%)
Ex-Dividend Date	Jun 13, 2025

Volume	1,498,245
Average Volume	3,356,631
Open	39.10
Previous Close	39.10
Day's Range	38.65 - 39.65
52-Week Range	23.10 - 41.85
Beta	0.33
RSI	75.27
Earnings Date	Aug 21, 2025

About HKG:1513

Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People’s Republic of China. The company offers Ilaprazole enteric-coated tablets and ilaprazole sodium for injection a series of bismuth potassium citrate products for gastrointestinal field; leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for assisted reproduction field; fluvoxamine maleate and perospirone hydrochloride tablets for psychiatric...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1985
• Employees: 9,067
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1513

Financial Performance

In 2024, HKG:1513's revenue was 11.81 billion, a decrease of -4.97% compared to the previous year's 12.43 billion. Earnings were 2.06 billion, an increase of 5.50%.

Financial numbers in CNY